Omnicell, Inc. (OMCL)

NASDAQ: OMCL · Real-Time Price · USD
43.80
+0.63 (1.46%)
At close: May 14, 2026, 4:00 PM EDT
43.20
-0.60 (-1.37%)
Pre-market: May 15, 2026, 7:34 AM EDT
Market Cap1.99B +35.7%
Revenue (ttm)1.23B +7.9%
Net Income20.43M -3.5%
EPS0.44 -2.8%
Shares Out 45.48M
PE Ratio99.53
Forward PE23.50
Dividendn/a
Ex-Dividend Daten/a
Volume456,237
Open43.62
Previous Close43.17
Day's Range42.54 - 43.85
52-Week Range26.85 - 55.00
Beta0.96
AnalystsBuy
Price Target55.83 (+27.47%)
Earnings DateApr 28, 2026

About OMCL

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-hous... [Read more]

Sector Healthcare
IPO Date Aug 7, 2001
Employees 3,525
Stock Exchange NASDAQ
Ticker Symbol OMCL
Full Company Profile

Financial Performance

In 2025, Omnicell's revenue was $1.18 billion, an increase of 6.53% compared to the previous year's $1.11 billion. Earnings were $2.05 million, a decrease of -83.62%.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for OMCL stock is "Buy." The 12-month stock price target is $55.83, which is an increase of 27.47% from the latest price.

Price Target
$55.83
(27.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Omnicell Transcript: Bank of America Global Healthcare Conference 2026

The conference highlighted a strategic focus on launching Titan XT and OmniSphere, driving a major product transition and targeting margin expansion through disciplined execution and investment. Management expects a multi-year capital cycle, stable hospital CapEx, and renewed optimism in retail pharmacy.

2 days ago - Transcripts

Omnicell to Present at the BofA Securities 2026 Healthcare Conference

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the BofA Securities 2026 Healthcare Conference.

10 days ago - Business Wire

Omnicell price target raised to $55 from $53 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Omnicell (OMCL) to $55 from $53 and keeps a Buy rating on the shares. Following the company’s beat and raise quarter, the firm…

15 days ago - TheFly

Omnicell appoints Rick Couldry as SVP, chief pharmacy and clinical officer

Omnicell (OMCL) announced that Rick Couldry has joined the Company as Senior Vice President, Chief Pharmacy and Clinical Officer. In this newly created position, Couldry will serve as Omnicell’s senio...

15 days ago - TheFly

Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer.

16 days ago - Business Wire

Omnicell price target raised to $70 from $60 at KeyBanc

KeyBanc raised the firm’s price target on Omnicell (OMCL) to $70 from $60 and keeps an Overweight rating on the shares. After a solid Q1, the firm continues to recommend…

16 days ago - TheFly

Omnicell price target raised to $70 from $60 at KeyBanc

KeyBanc raised the firm’s price target on Omnicell (OMCL) to $70 from $60 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1…

16 days ago - TheFly

Omnicell Earnings Call Transcript: Q1 2026

Q1 2026 results exceeded guidance with 15% revenue growth, improved margins, and strong recurring revenue momentum. Full-year guidance was raised for EBITDA and EPS, supported by robust demand for new platforms and disciplined cost management.

17 days ago - Transcripts

Omnicell reports Q1 adjusted EPS 55c, consensus 33c

Reports Q1 revenue $310M, consensus $304.06M. “We delivered a strong start to 2026, driven by solid execution and sustained demand for our points of care solutions,” said Randall Lipps, chairman,…

17 days ago - TheFly

Omnicell sees Q2 adjusted EPS 40c-48c, consensus 42c

Sees Q2 revenue $307M-$313M, consensus $304.83M.

17 days ago - TheFly

Omnicell raises FY26 adjusted EPS view to $1.80-$2.00 from $1.65-$1.85

FY26 consensus $1.77. Backs FY26 revenue view $1.215B-$1.255B, consensus $1.24B.

17 days ago - TheFly

Omnicell Announces First Quarter 2026 Financial Results

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces First Quarter 2026 Financial Results.

17 days ago - Business Wire

Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026.

4 weeks ago - Business Wire

Omnicell management to meet with Piper Sandler

Meeting to be held on March 12 hosted by Piper Sandler.

2 months ago - TheFly

Omnicell management to meet virtually with Benchmark

Virtual Meeting to be held on March 11 hosted by Benchmark.

2 months ago - TheFly

Omnicell price target lowered to $49 from $63 at Piper Sandler

Piper Sandler lowered the firm’s price target on Omnicell (OMCL) to $49 from $63 and keeps an Overweight rating on the shares. The firm notes the company reported mixed Q4…

3 months ago - TheFly

Omnicell Earnings Call Transcript: Q4 2025

Delivered strong Q4 and FY 2025 results, exceeding guidance for revenue, bookings, and ARR. Launched Titan XT and expanded OmniSphere, driving robust demand and competitive wins. FY 2026 guidance anticipates continued growth, with investments in innovation, cloud, and sales force.

3 months ago - Transcripts

Omnicell reports Q4 adjusted EPS 40c, consensus 50c

Reports Q4 revenue $314M, consensus $313.36M. “We finished 2025 with solid fourth quarter financial results, delivering full year 2025 total revenues, product bookings and annual recurring revenues al...

3 months ago - TheFly

Omnicell sees Q1 adjusted EPS 26c-36c, consensus 27c

Sees Q1 revenue $300M-$310M, consensus $280.84M.

3 months ago - TheFly

Omnicell sees FY26 adjusted EPS $1.65-$1.85, consensus $1.88

Sees FY26 revenue $1.215B-$1.255B, consensus $1.24B.

3 months ago - TheFly

Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results.

3 months ago - Business Wire

Omnicell management to meet with Piper Sandler

Meeting to be held in Boston on February 11 and in New York on February 12 hosted by Piper Sandler.

3 months ago - TheFly

Omnicell upgraded to Buy at BofA on new product cycle

As previously reported, BofA analyst Allen Lutz upgraded Omnicell (OMCL) to Buy from Neutral with a price target of $70, up from $53, as the firm sees a significant upside…

3 months ago - TheFly

Omnicell upgraded to Buy from Neutral at BofA

BofA upgraded Omnicell (OMCL) to Buy from Neutral with a price target of $70, up from $53.

3 months ago - TheFly

Omnicell price target raised to $60 from $50 at Benchmark

Benchmark raised the firm’s price target on Omnicell (OMCL) to $60 from $50 and keeps a Buy rating on the shares ahead of the company reporting its 2026 results on…

3 months ago - TheFly